ASMB Company Profile and Key Details

Q: Who are the executives of ASMB?

Dr. William E. Delaney IV, Ph.D.Chief Scientific OfficerMs. Michele AndersonChief Devel. OfficerAmy Figueroa C.F.A.Investor Relations ConsultantDr. John G. McHutchison A.O., FRACP, M.D.Chief Executive Officer & DirectorMs. Jennifer A. Troia MHROD, SHRM-SCP, SPHRChief HR OfficerDr. Adam ZlotnickCo-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory BoardMr. Jason A. OkazakiChief Operating Officer, Chief Executive Officer, Pres & DirectorMr. Thomas E. RollinsExecutive OfficerDr. Tharaknath RaoHead of Microbiome Clinical Devel. & Senior Vice PresidentDr. Nicole S. White Ph.D.Chief Manufacturing OfficerDr. Richard J. ColonnoSenior AdvisorJeanette M BjorkquistExecutive Director of Accounting & TreasuryShannon RyanSenior Vice President of Investor Relations, Corporation Affairs & Alliance Management

NASDAQ : ASMB

Assembly Biosciences

$25.15

0.71+2.91%

At Close 4:00 PM

57.89

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Assembly Biosciences, Inc. (ASMB) stock surged +2.91%, trading at $25.15 on NASDAQ, up from the previous close of $24.44. The stock opened at $24.50, fluctuating between $24.44 and $26.14 in the recent session.

Stock Snapshot

24.44

Prev. Close

399.71M

Market Cap

24.44

Day Low

314.38

P/E Ratio

0.08

EPS (TTM)

4.1

Cash Flow per Share

24.5

Open

15.89M

Number of Shares

26.135

Day High

46.84%

Free Float in %

7.5

Book Value

267.63K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 22, 2026	24.50	26.14	24.44	25.15	286.84K
Jun 18, 2026	24.60	25.93	24.22	24.44	298.86K
Jun 17, 2026	23.25	24.51	23.20	24.15	133.83K
Jun 16, 2026	23.23	23.42	22.58	23.33	116.94K
Jun 15, 2026	23.67	24.15	23.07	23.34	173.21K
Jun 12, 2026	22.60	23.69	22.35	22.96	144.39K
Jun 11, 2026	22.26	22.62	21.80	22.53	290.55K
Jun 10, 2026	22.50	23.99	22.18	22.26	195.48K
Jun 09, 2026	23.40	23.82	22.20	22.72	243.77K
Jun 08, 2026	23.47	23.66	22.24	22.56	153.13K
Jun 05, 2026	24.00	24.00	22.24	22.90	130.63K
Jun 04, 2026	24.57	25.05	23.88	24.11	215.19K
Jun 03, 2026	24.57	24.65	24.00	24.57	180.15K
Jun 01, 2026	28.25	28.75	26.58	26.92	218.92K
May 29, 2026	27.73	28.52	27.25	27.66	138.76K
May 28, 2026	27.30	27.78	27.00	27.73	115.52K
May 27, 2026	28.61	28.91	27.08	27.40	148.99K
May 26, 2026	28.33	29.05	27.41	28.75	244.65K
May 22, 2026	28.61	31.89	27.64	28.34	958.89K
May 21, 2026	26.05	26.60	25.76	26.50	63.89K

Contact Details

South San Francisco, CA 94080

United States

https://www.assemblybio.com 833 509 4583

About Company

Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.

Stock Peers

ARGX

26.03+2.97%

argenx SE$903.75 REGN

2.56+0.42%

Regeneron Pharmaceuticals, Inc.$612.50 UTHR

1.70998+0.32%

United Therapeutics Corporation$538.30 MDGL

7.13+1.41%

Madrigal Pharmaceuticals, Inc.$512.88 VRTX

15.16+3.36%

Vertex Pharmaceuticals Incorporated$466.79 KRYS

-4.63-1.33%

Krystal Biotech, Inc.$343.43 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

21.08+7.47%

Praxis Precision Medicines, Inc.$303.39 ALNY

8.32+2.99%

Alnylam Pharmaceuticals, Inc.$286.41 LGND

-12.71-4.62%

Ligand Pharmaceuticals Incorporated$262.17

Company Overview

Assembly Biosciences, Inc. (NASDAQ:ASMB) closed at $25.15 USD, gaining $0.71 (2.91%) from the previous close of $24.44. The stock is currently mid-range between its 52-week high and low $16.81 and $39.71. With a market capitalization of about $399.71 million, Assembly Biosciences, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.08). Key stats such as the average daily volume over the past year has been around 152.25 thousand shares, trading with heavier-than-usual volume. Headquartered in South San Francisco, CA, Assembly Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jason A. Okazaki, the company employs approximately 73 people and listed since December 17, 2010. Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States.

Technical Performance

ASMB has shown weak momentum, losing -13.35% over the past week and -9.0% over the past quarter, though year-to-date performance is down -21.2%. Short-term trend indicators are mixed aligned (SMA20 7.76%, SMA50 -0.62%, SMA200 16.64%). The stock’s 14-day RSI is 54.31 (neutral), while the ATR of 1.8 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -25.48% below its high and over 281.81% above its low. Average 10-day trading volume of 201.93 thousand shares is slightly above the 3-month average of 156.30 thousand, indicating heightened recent market interest.

Valuation Metrics

Assembly Biosciences, Inc. trades at a P/E ratio of -42.46, slightly below the S&P 500 average, with a price-to-sales ratio of 5.5 and a price-to-book ratio of 2.1 suggesting the stock is closer to book value. The P/FCF stands at -9.82, also below market averages.

Dividend & Fair Value

Assembly Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.98. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Assembly Biosciences, Inc. generated EPS of -$4.80 over the past year. Five-year average earnings growth is 31.58%. The latest quarter delivered EPS of -$0.54. The next quarter is forecast at -$0.86. Next year's EPS is expected at $5.91. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $50.00 to $38.00. The high target offers 98.81% upside. The low target suggests 51.09% downside. The mean target is $45.27. This offers 80.0% upside. Assembly Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by -16.92%. The prior quarter beat by -586.27%. Over the last six quarters, Apple has recorded several small beats. These include -10.29% in March 20, 2025.

Shareholding & Insider Activity

Assembly Biosciences, Inc. has 19.82 million shares outstanding. The public float is 8.80 million shares, elevated short interest at 11.41% of float. This equals 1.68 million shares. The short ratio is 9.29 days. Institutional investors hold 82.95% of the float. Insiders own 32.3%. GILEAD SCIENCES, INC. holds 1.15 million shares, Schornstein Alexander has 723.11 thousand shares and Small Derek A has 668.09 thousand shares. Over the past six months, insider transactions show net selling. They sold 54.00 shares across 3 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Assembly Biosciences generated $7.16M in revenue, or $1.56 per share. Gross margin was 93.72%, operating margin -902.50%, and net profit margin -854.78%. Returns are negative, with ROA at -44.54% and ROE at -148.98%.
On valuation metrics, Assembly Biosciences trades at a P/E of -42.46, P/S of 5.50 and P/B of 2.10. The current ratio is 6.65 and quick ratio is 6.65. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -23.15 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -15.96.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Assembly Biosciences posted revenue of $7.16M, down slightly from $0.00 in the prior quarter. Gross profit was $6.71M (margin 93.72%). Operating income was - $64.65M (margin -902.5%). Net income was- $61.23M (EPS - $13.38).
The company ended the quarter with $130.25M in cash and short-term investments, a total debt of $2.34M, and net debt of - $17.50M. Total assets were $137.47M, with equity of $41.10M. Financials further reflected stability, with operating cash flow of $22.74M, free cash flow of $22.49M, and capital expenditures of - $255.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Assembly Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -8.59%, with price expected at $22.99 by July 06, 2026, within a range of $20.92 to $25.16 3-Month Outlook: Projected fall of -43.82%, reaching $14.13 by September 16, 2026, with a range of $12.58 to $15.14. 1-Year Outlook: Projected gain of 28.75%, with price at $32.38 by June 22, 2027, within a range of $31.00 to $34.22.

Key Takeaways

Assembly Biosciences, Inc. (NASDAQ:ASMB) shares are down -21.2% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Assembly Biosciences, Inc. trading at a premium to the broader market with a P/E of -42.46. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $36.67, suggesting 45.81% upside. Our AI forecast model points to short-term weakness (-8.59% over two weeks), a medium-term fall (-43.82% over three months), and a longer-term gain (28.75% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Assembly Biosciences, Inc. (ASMB) stock price?

Assembly Biosciences, Inc. (NASDAQ: ASMB) stock price is $25.15 in the last trading session. During the trading session, ASMB stock reached the peak price of $26.14 while $24.44 was the lowest point it dropped to. The percentage change in ASMB stock occurred in the recent session was 2.91% while the dollar amount for the price change in ASMB stock was $0.71.

ASMB's industry and sector of operation?

The NASDAQ listed ASMB is part of Biotechnology industry that operates in the broader Healthcare sector. Assembly Biosciences, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ASMB?

Dr. William E. Delaney IV, Ph.D.
Chief Scientific Officer
Ms. Michele Anderson
Chief Devel. Officer
Amy Figueroa C.F.A.
Investor Relations Consultant
Dr. John G. McHutchison A.O., FRACP, M.D.
Chief Executive Officer & Director
Ms. Jennifer A. Troia MHROD, SHRM-SCP, SPHR
Chief HR Officer
Dr. Adam Zlotnick
Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board
Mr. Jason A. Okazaki
Chief Operating Officer, Chief Executive Officer, Pres & Director
Mr. Thomas E. Rollins
Executive Officer
Dr. Tharaknath Rao
Head of Microbiome Clinical Devel. & Senior Vice President
Dr. Nicole S. White Ph.D.
Chief Manufacturing Officer
Dr. Richard J. Colonno
Senior Advisor
Jeanette M Bjorkquist
Executive Director of Accounting & Treasury
Shannon Ryan
Senior Vice President of Investor Relations, Corporation Affairs & Alliance Management

How ASMB did perform over past 52-week?

ASMB's closing price is 49.7% higher than its 52-week low of $16.81 where as its distance from 52-week high of $39.71 is -36.67%.

How many employees does ASMB have?

Number of ASMB employees currently stands at 73.

Link for ASMB official website?

Official Website of ASMB is: https://www.assemblybio.com

How do I contact ASMB?

ASMB could be contacted at phone 833 509 4583 and can also be accessed through its website. ASMB operates from 331 Oyster Point Boulevard, South San Francisco, CA 94080, United States.

How many shares of ASMB are traded daily?

ASMB stock volume for the day was 267.63K shares. The average number of ASMB shares traded daily for last 3 months was 152.25K.

What is the market cap of ASMB currently?

The market value of ASMB currently stands at $399.71M with its latest stock price at $25.15 and 15.89M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	73
Beta	1.08
Sales or Revenue	$7.16M
5Y Sales Change%	1.41%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ASMB Company Profile and Key Details

Assembly Biosciences

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics